Baltimore-based Cerecor obtains depression drug rights
2:45 pm Fri, April 19, 2013
Posted: 2:45 pm Fri, April 19, 2013
By Daily Record Staff
Cerecor Inc., of Baltimore, a biopharmaceutical company focused on developing and commercializing prescription drugs involving the human nervous system, said it has acquired from Merck & Co. the exclusive, worldwide rights to a drug called MK-0657, which it said has the potential to treat depression. Merck originally developed MK-0657 for treatment of Parkinson’s disease.
Already a paid subscriber but not registered for online access yet? For instructions on how to get premium web access, click here.